Ken Belotsky (L) and Shlomi Raz
December 11, 2024 07:00 AM EST
Financing
Startups

Ex­clu­sive: Negev Labs un­veils with $30M in as­sets, striv­ing to build a net­work of psy­che­del­ic biotechs

Max Bayer

Pharma Reporter

A new psy­che­del­ic-fo­cused start­up in­cu­ba­tor is de­but­ing, backed by an in­vestor be­hind some of the most promi­nent biotechs in the space. The main theme of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Eli Lil­ly has tapped tele­health start­up Ro to dis­trib­ute its sin­gle-dose Zep­bound vials

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times